Dr. Asi Haviv joined Chiasma in 2012 as Vice President Clinical Development and led the development of MYCAPSSA for acromegaly. Prior to Chiasma, he was a Director at Teva Pharmaceuticals, Global Branded R&D, where he established and led the clinical development strategy of various innovative products in the inflammatory/autoimmune, neurology, and endocrinology therapeutic areas. He also served as a member of the autoimmune search and evaluation team at Teva’s Global Branded Products Business Development group, responsible for the clinical evaluation of in-licensing opportunities. Dr. Haviv brings to Chiasma substantial experience in drug development and interpretation of clinical data together with expertise in due diligence processes and clinical evaluation of product candidate opportunities. He received his Doctor of Dental Medicine (D.M.D) from the Hadassah School of Dental Medicine, the Hebrew University of Jerusalem, where he also completed his residency to become a board-certified oral medicine specialist.
VP Clinical Development